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Abstract. 
 
We have examined the roles of the p85/
p110
 
a
 
 and hVPS34 phosphatidylinositol (PI) 3
 
9
 
-kinases 
in cellular signaling using inhibitory isoform-specific 
antibodies. We raised anti-hVPS34 and anti-p110
 
a
 
 anti-
bodies that specifically inhibit recombinant hVPS34 
and p110
 
a
 
, respectively, in vitro.
 
 
 
We used the antibod-
ies to study cellular processes that are sensitive to low-
dose wortmannin. The antibodies had distinct effects 
on the actin cytoskeleton; microinjection of anti-p110
 
a
 
 
antibodies blocked insulin-stimulated ruffling, whereas 
anti-hVPS34 antibodies had no effect. The antibodies 
also had different effects on vesicular trafficking. Mi-
croinjection of inhibitory anti-hVPS34 antibodies, but 
not anti-p110
 
a
 
 antibodies, blocked the transit of inter-
nalized PDGF receptors to a perinuclear compartment, 
and disrupted the localization of the early endosomal 
protein EEA1. Microinjection of anti-p110
 
a
 
 antibod-
ies, and to a lesser extent anti-hVPS34 antibodies, re-
duced the rate of transferrin recycling in CHO cells. 
Surprisingly, both antibodies inhibited insulin-stimu-
lated DNA synthesis by 80%. Injection of cells with an-
tisense oligonucleotides derived from the hVPS34 se-
quence also blocked insulin-stimulated DNA synthesis, 
whereas scrambled oligonucleotides had no effect. In-
terestingly, the requirement for p110
 
a
 
 and hVPS34 oc-
curred at different times during the G1ÐS transition. 
Our data suggest that different PI 3
 
9
 
-kinases play dis-
tinct regulatory roles in the cell, and document an unex-
pected role for hVPS34 during insulin-stimulated mito-
genesis.
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P
 
hosphatidylinositol (
 
PI
 
)
 
1
 
 
 
3
 
9
 
-kinases are lipid ki-
nases implicated in a wide range of cellular phe-
nomena (Fruman et al., 1998). PI 3
 
9
 
-kinases have
been grouped into three classes based on their use of dif-
ferent phosphoinositide substrates (Vanhaesebroeck et al.,
1997). Class I enzymes use PI, PI[4]P, and PI[4,5]P
 
2
 
 as sub-
strates, producing PI[3]P, PI[3,4]P
 
2
 
, and PI[3,4,5]P
 
3
 
. They
include the well-studied p85/p110 PI 3
 
9
 
-kinases, which are
activated by receptor tyrosine kinases, and the PI3K-
 
g
 
,
which is activated by 
 
bg
 
-subunits from trimeric G proteins
(Kapeller and Cantley, 1994; Stoyanov et al., 1995; Ste-
phens et al., 1997). Class II enzymes are larger in size
(170Ð210 kD) and contain a COOH-terminal C2 domain
(MacDougall et al., 1995; Molz et al., 1996; Virbasius et al.,
1996; Domin et al., 1997). These enzymes use both PI and
PI[4]P as substrates, but will not produce PIP
 
3
 
 from
PI[4,5]P
 
2
 
. Class III enzymes include the 
 
Saccharomyces
cerevisiae
 
 enzyme VPS34 and its homologues in 
 
Schizosac-
charomyces pombe
 
, 
 
Dictyostelium discoideum
 
, 
 
Drosoph-
ila
 
, and humans (Herman and Emr, 1990; MacDougall et
al., 1995; Volinia et al., 1995; Takegawa et al., 1995; Zhou
et al., 1995; Linassier et al., 1997). VPS34 and its homo-
logues are limited to production of PI[3]P from PI. In
yeast, VPS34 associates in vivo with a myristylated serine
kinase, VPS15 (Stack et al., 1993), and this association is
critical for VPS34 function (Stack et al., 1993). The human
homologue of VPS15, p150, is also a myristylated protein
kinase that binds to hVPS34 in vivo
 
 
 
and increases its lipid
kinase activity twofold in vitro (Panaretou et al., 1997).
The lipid products of the PI 3
 
9
 
-kinases are not substrates
for known phospholipases and appear to function as sec-
ond messengers (Serunian et al., 1989). PI[3,4,5]P
 
3
 
 may di-
rectly activate its effector enzymes, such as calcium-inde-
pendent protein kinase C isoforms (Toker et al., 1994,
1995). Alternatively, production of 3-phosphoinositides in
cellular membranes may recruit signaling molecules that
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contain specialized lipid-binding domains (Lemmon et al.,
1996). Examples include the serine kinase Akt/PKB and
its upstream activator the 3-phosphoinositideÐdependent
kinase-1, which contain Pleckstrin homology domains that
bind PI[3,4]P2 and PI[3,4,5]P
 
3
 
 (for review see Toker and
Cantley, 1997), and the endosomal protein EEA1, which
contains a zinc finger domain that binds to PI[3]P (Sten-
mark et al., 1996; Patki et al., 1997).
The functions of the different PI 3
 
9
 
-kinases in mamma-
lian cells have been studied using tools that vary signifi-
cantly in their specificity. Mutant p85 molecules or SH2
domains from p85 produce dominant-negative phenotypes
in microinjected or transfected cells (Jhun et al., 1994;
Hara et al., 1995), and mutagenesis of p85 binding sites in
receptor tyrosine kinases blocks p85/p110 activation (for
review see Cantley et al., 1991). However, these ap-
proaches do not distinguish between different p110 iso-
forms which should all bind p85. Less-specific approaches
include overexpression of the p110
 
a
 
 PI 3
 
9
 
-kinase, which
produces PI[3]P, PI[3,4]P
 
2
 
, and PI[3,4,5]P
 
3
 
 and can feed
into pathways normally regulated by class I, II, or III en-
zymes. Similarly, treatment of cells with wortmannin in-
hibits both the mammalian class I and class III enzymes at
low nanomolar doses (Vanhaesebroeck et al., 1997). (Un-
like the mammalian enzyme, the yeast VPS34 is relatively
insensitive to wortmannin [Schu et al., 1993].) The use of
wortmannin is further complicated by the fact that inhibi-
tion of mammalian class II PI 3
 
9
 
-kinases requires high
nanomolar to micromolar concentrations (Domin et al.,
1997). These doses also inhibit PI 4-kinases, and could
affect cellular levels of PI[4,5]P
 
2
 
 (Meyers and Cantley,
1997).
The p85/p110 PI 3
 
9
 
-kinases have been implicated in mi-
togenic signaling, regulation of the actin cytoskeleton, re-
sistance to apoptosis, and trafficking of the Glut 4 glucose
transporter (Fruman et al., 1998). In contrast, little is
known about the function of class III PI 3
 
9
 
-kinases in
mammalian cells. In 
 
S. cerevisiae
 
 and
 
 S. pombe
 
, VPS34-
null strains show disruption of vacuolar sorting at permis-
sive and nonpermissive temperatures, and reduced growth
at elevated temperatures (Herman and Emr, 1990; Take-
gawa et al., 1995). The authors suggest that the combined
stress of high temperature plus abnormal vacuolar func-
tion may inhibit growth at high temperature. Alterna-
tively, they suggest that some vacuolar function might
be required for high temperature growth (Takegawa et
al., 1995). In 
 
D. discoideum
 
, reduced expression of the
DdPIK5 homologue leads to reduced growth on bacterial
lawns but not in suspension culture (Zhou et al., 1995),
suggesting a lysosomal defect that causes a reduced ability
to utilize bacteria as food. On the other hand, a complete
gene knockout of the 
 
D. discoideum
 
 VPS34 homologue is
lethal, implying that VPS34 may be essential for growth.
Our approach has been to study the intracellular func-
tion of distinct PI 3
 
9
 
-kinase by developing isoform-specific
inhibitory antiÐPI 3
 
9
 
-kinase antibodies. We have focused
on the role of p110
 
a
 
 and hVPS34, which are wortmannin-
sensitive class I and III enzymes, in a number of wortman-
nin-sensitive responses. We find that insulin-stimulated
reorganization of filamentous actin is inhibited by micro-
injection of antibodies to p110
 
a
 
 but not hVPS34. In con-
trast, antibodies to both enzymes inhibit vesicular traffick-
ing: anti-hVPS34 antibodies interfere with the sorting of
endocytosed PDGF receptors, disrupt the localization of
the early endosomal protein EEA1, and modestly inhibit
transferrin recycling, whereas anti-p110
 
a
 
 antibodies strongly
inhibit transferrin recycling. Surprisingly, antibodies to
hVPS34 as well as p110
 
a
 
 inhibit insulin-stimulated DNA
synthesis. However, the requirement for p110
 
a
 
 and
hVPS34 occur at different times during the G1ÐS transi-
tion. These studies represent a first step in the assignment
of distinct PI 3
 
9
 
-kinases to the regulation of distinct cellu-
lar events.
 
Materials and Methods
 
Cells
 
Growth of GRC-LR
 
1
 
73 cells, an insulin-responsive derivative of CHO
cells, has been previously described (Pollard and Stanners, 1979; McIlroy
et al., 1997). Hep G2 cells expressing the wild-type PDGF receptor (Va-
lius and Kazlauskas, 1993) were generously provided by A. Kazlauskas
(Harvard University, Cambridge, MA) and were grown in DME contain-
ing 10% fetal bovine serum. Trvb-1 cells, a CHO cell line expressing the
human transferrin receptor (McGraw et al., 1987), were generously pro-
vided by T. McGraw (Cornell University School of Medicine, New York,
NY) and were grown in 
 
a
 
-MEM containing 10% fetal bovine serum.
 
Antibodies
 
Anti-hVPS34 antibodies were raised in New Zealand white rabbits against
a peptide corresponding to residues 871Ð887 of the human VPS34 se-
quence, AVVEQIHKRAQYWRK (Volinia et al., 1995). Antibodies were
purified using an affinity column made from the same peptide coupled to
CNBr Sepharose (Pharmacia Biotech, Piscataway, NJ). Antibodies for mi-
cronjection were dialyzed into phosphate-buffered saline and concen-
trated to 3 mg/ml. Antibodies to p110
 
a
 
 have been previously described
(McIlroy et al., 1997). Anti-EEA1 antibodies were purchased from Trans-
duction Laboratories (Lexington, KY).
 
Antisense Oligonucleotides
 
Phosphorothioate oligonucleotides were synthesized (Genelink, Thorn-
wood, NY) so as to be anticomplimentary to sequences from hVPS34.
AS1: TCCCCCCATCGCACCGTCTGC (based on nucleotides 36Ð56 in
the hVPS34 GenBank/EMBL/DDBJ sequence Z46973). AS2: AAACTT-
CTCTGCTTCCCCCAT (based on nucleotides 48Ð68); AS3: TCTGATC-
CATCTGC-TTCTACA (based on nucleotides 491Ð511).
 
Production of Recombinant p110
 
a
 
 and hVPS34
 
Sf-9 cells were infected with recombinant baculovirus for bovine p110
 
a
 
(cDNA provided by M. Waterfield, Ludwig Institute for Cancer Re-
search, London, UK), hVPS34 (virus provided M. Waterfield) or p110
 
b
 
(virus provided by A. Morris, State University of New York at Stony
Brook, Stony Brook, NY). After 2 d in culture, the cells were washed in
ice-cold PBS and lysed by freeze-thawing in 10 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 100 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml leupeptin, and 350 
 
m
 
g/
ml PMSF. After removal of particulate material by centrifugation at
12,000 
 
g
 
, the lysates were assayed directly for PI 3
 
9
 
-kinase activity as de-
scribed below.
 
In Vitro PI 3
 
9
 
-Kinase Assays
 
Sf-9 lysates containing recombinant p110
 
a
 
, p110
 
b
 
, or hVPS34 were incu-
bated in the absence or presence of antibodies as described in the text. PI
3
 
9
 
-kinase activity was then assayed using sonicated bovine liver phosphati-
dylinositol (200 
 
m
 
g/ml), ATP (45 
 
m
 
M), and 10 mM MgCl
 
2
 
 or MnCl
 
2
 
 as pre-
viously described (Rordorf-Nikolic et al., 1995). Where indicated, p110
 
a
 
or hVPS34 was first immunoprecipitated from Sf-9 or CHO detergent ly-
sates with anti-p110
 
a
 
 or anti-hVPS34 antibodies. The protein A pellets
were washed and assayed as described by Ruderman et al. (1990). In some
cases, the enzymes were first eluted from the antibody by incubation for
30 min at 30
 
8
 
C in the presence of 100 
 
m
 
M hVPS34-derived peptide (Field
et al., 1988). 
Siddhanta et al. 
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[
 
35
 
S]Methionine 
 
Cells were incubated for 5 h in cysteine/methionine-free medium contain-
ing 1 mCi/ml [
 
35
 
S]cysteine/methionine (Easy-tag, New England Nuclear,
Boston, MA). The cells were then washed with phosphate-buffered saline,
lysed in under non-denaturing (Yu et al., 1998) or denaturing (Martys et al.,
1996) conditions, and then proteins were immunoprecipitated with anti-
hVPS34 or anti-p110
 
a
 
 antibodies and absorbed to protein AÐSepharose
beads. The beads were washed five times in RIPA buffer, followed by an
additional four washes in RIPA containing 1 M NaCl. After a final wash
in PBS, the proteins were eluted, separated by SDS-PAGE, and then visu-
alized by autoradiography.
 
Microinjection
 
Cells were grown on polylysine-coated glass coverslips. GRC-LR
 
1
 
73 cells
were transferred to medium containing 1% fetal bovine serum for 48 h be-
fore injection. HepG2/PDGF-R cells were incubated in serum-free me-
dium overnight before injection. Microinjections were conducted using an
Eppendorf semiautomated microinjection system and needles pulled on a
Sutter p-87 micropipette puller. Antibodies (2Ð4 mg/ml) or oligonucle-
otides (10 
 
m
 
M) were mixed with nonspecific rabbit IgG in PBS, pH 7.4, to
a final antibody concentration of 3 mg/ml. Cells were allowed to recover
for 2 h before further manipulation.
 
Actin Reorganization
 
GRC-LR
 
1
 
73 cells were injected with control or antiÐPI 3
 
9
 
-kinase anti-
bodies as indicated. After a 2-h recovery period, the cells were stimulated
with insulin for 7 min, fixed with 3.7% formaldehyde, and stained with
FITC anti-rabbit antibodies (to detect injected cells) or rhodamine-phal-
loidin (Molecular Probes, Eugene, OR), to visualize the actin cytoskele-
ton (Segall et al., 1996).
 
EEA1 Staining
 
Cells were injected with control IgG or antiÐPI 3
 
9
 
-kinase antibodies, al-
lowed to recover for 2 h, and then fixed with 3.7% formaldehyde for 20
min on ice. The cells were permeabilized with methanol on dry ice,
blocked with 10% goat serum, and stained with FITC anti-rabbit IgG (to
detect injected cells) or anti-EEA1 antibodies (Transduction Laborato-
ries). EEA1 staining was visualized using the Renaissance signal amplifi-
cation kit (New England Nuclear Life Science Products, Boston, MA), ac-
cording to the manufacturerÕs instructions.
 
Transferrin Recycling
 
Trvb-1 cells were injected with control or antiÐPI 3
 
9
 
-kinase antibodies as
indicated, and allowed to recover for 2 h. The cells were loaded with Cy3-
transferrin for 2 h, washed, and then fixed immediately or after an addi-
tional hour in transferrin-free medium as previously described (Martys et al.,
1996). The cells were permeabilized with saponin as described (McGraw
et al., 1987) and stained with FITC anti-rabbit antibodies to visualize in-
jected cells.
 
PDGF Receptor Trafficking
 
PDGF receptor internalization was measured as described by Joly et al.
(1994). HepG2/PDGF-R cells were incubated in serum-free medium over-
night. The cells were injected with control or antiÐPI 3
 
9
 
-kinase antibodies
and allowed to recover for 2 h. The cells were then incubated for 70 min
on ice with monoclonal anti-PDGF receptor antibody (20 
 
m
 
g/ml final; Cal-
biochem-Novabiochem, La Jolla, CA) and recombinant human PDGF-
BB (20 ng/ml; Calbiochem-Novabiochem). The cells were either fixed im-
mediately or rapidly warmed by immersion in medium at 37
 
8
 
C for 10 min
before fixation. The cells were stained with FITC antiÐrabbit antibodies to
visualize injected cells, or Cy3Ðanti-mouse antibodies to visualize PDGF
receptors.
 
BrdU Incorporation
 
After injection, cells were kept in medium containing 1% FBS or stimu-
lated with 100 nM insulin as indicated. When indicated, the cells were in-
jected at various times after insulin stimulation. 16 h after the onset of in-
sulin stimulation, the cells were incubated with 100 
 
m
 
M BrdU for 2 h and
fixed in 3.7% formaldehyde. Nuclear DNA was denatured by treating the
cells with 4 N HCl for 3 min, and the cells were permeabilized in methanol
at 
 
2
 
20
 
8
 
C and stained with rhodamine-conjugated anti-BrdU antibody to
measure DNA synthesis, and FITC-conjugated anti-rabbit IgG to deter-
mine microinjected cells. The percentage of microinjected cells that was
positive for BrdU staining was determined. Data from each experiment
reflects the counting of 
 
z
 
100 injected cells per condition. The mean and
SEM values were generated by pooling percentages from different experi-
ments, where
 
 n 
 
5 
 
the number of separate experiments.
 
Results
 
Characterization of Anti-p110
 
a
 
 and
Anti-hVPS34 Antibodies
 
We have previously described antibodies to residues 1054Ð
1068 of p110
 
a
 
, which inhibit p110
 
a
 
 in vitro and in microin-
jected cells (McIlroy et al., 1997). We also raised antibod-
ies against residues 871Ð887 at the COOH terminus of the
human VPS34 primary sequence. To test the specificity of
the antibodies, we labeled three different cell lines for 5 h
with a mixture of [
 
35
 
S]methionine and [
 
35
 
S]cysteine. The
lines were: a CHO-derived line selected for tight quies-
cence during serum withdrawal (Pollard and Stanners,
1979) (GRC-LR
 
1
 
73), a CHO line expressing the human
transferrin receptor (McGraw et al., 1987) (Trvb-1), and a
HepG2 line expressing the human PDGF receptor (Valius
and Kazlauskas, 1993). We then lysed the cells under non-
Figure 1. Immunoprecipitation of p110a and
hVPS34 from metabolically labeled cells. Hep G2
cells expressing the human PDGF receptor,
Trvb-1, and GRC-LR173 cells were labeled for
5 h in medium containing 0.2 mCi/ml [35S]methi-
onine/[35S]cysteine. The cells were lysed as de-
scribed in the text, and immunoprecipitates were
prepared using control IgG, anti-p110a (left) or
anti-hVPS34 antibody (right). The samples were
washed and then proteins were eluted and sepa-
rated by SDS-PAGE and visualized by autora-
diography. The data is representative of three
experiments.The Journal of Cell Biology, Volume 143, 1998 1650
denaturing and denaturing conditions, and performed im-
munoprecipitations with control IgG or the anti-PI kinase
antibodies. The anti-p110a antibodies were ineffective un-
der denaturing conditions, but under nondenaturing con-
ditions precipitated a single 110-kD band from all three
cell lines (Fig. 1, left). The p85 regulatory subunit of p85/
p110 PI 39-kinase was not observed in these experiments,
presumably because p110a has significantly more cysteine
and methionine residues (70, versus 16 for p85) and turns
over more rapidly than p85 (Yu et al., 1998). The anti-
hVPS34 antibodies was effective under denaturing condi-
tions and precipitated a major specific 100-kD band from
all three cell lines (Fig. 1, right). Additional bands minor
were observed but were also present after immunoprecipi-
tation with control IgG, and therefore reflect nonspecific
interactions.
We further characterized the new anti-hVPS34 antibod-
ies. They could immunoprecipitate recombinant human
hVPS34 from Sf-9 lysates (Fig. 2 A). The antibody also
precipitate a PI 39-kinase activity from CHO lysates; this
activity was manganese dependent, consistent with the ion
specificity of hVPS34 (Fig. 2 B) (Volinia et al., 1995). Al-
though we could measure PI kinase activity in the anti-
hVPS34 immunoprecipitates, the antibody was in fact in-
hibitory toward hVPS34. Fig. 2 C shows that the activity of
immunoprecipitated recombinant hVPS34 was increased
when eluted from antibodyÐprotein A beads by incubation
with the antigen peptide. Inhibition of hVPS34 could be
directly measured in a soluble in vitro assay with recom-
binant hVPS34. hVPS34 activity was inhibited 75% by
anti-hVPS34 antibodies, but was unaffected by a previ-
ously described antibody that binds and inhibits the p110a
PI 39-kinase (Fig. 2 D, left). Importantly, the antiÐhVPS34-1
antibody had no effect on the activity of recombinant
p110a (Fig. 2 D, right). In contrast, anti-p110a antibody
inhibited p110a by 80%. Neither antibody inhibited the
activity of recombinant p110b (data not shown). Inhibition
of hVPS34 by the anti-hVPS34 antibody was dose depen-
dent (Fig. 2 E).
Role of p110a and hVPS34 in Insulin-stimulated 
Membrane Ruffling
We used the isoform-specific antibodies to examine the
roles of p110a and hVPS34 in the regulation of the actin
cytoskeleton. GRC-LR173 cells were microinjected with
control IgG or anti-PI kinase antibody, incubated in the
absence or presence of 100 nM insulin for 7 min, and then
fixed. Cells were stained with FITC-labeled anti-rabbit
antibodies to identify microinjected cells (Fig. 3, left), or
rhodamine-phalloidin, to visualize filamentous actin (Fig.
3, right; asterisks, injected cells). In quiescent cells injected
with control IgG, rhodamine-phalloidinÐstained cells ap-
peared flat with prominent stress fibers (Fig. 3, A and B).
Quiescent cells injected with anti-hVPS34 antibodies (Fig.
3, E and F) or anti-p110a antibodies (Fig. 3, I and J) were
similar to the IgG-injected cells in appearance. When IgG-
injected cells were stimulated with insulin for 7 min, prom-
inent actin-rich projections appeared at the periphery of
the cells (Fig. 3, C and D). These projections appear some-
what blurry, as they extend out of the plane of focus used
to visualize the stress fibers. In cells injected with anti-
hVPS34 antibodies, insulin-stimulation of actin-rich pro-
jections was also apparent (Fig. 3, G and H). However, in-
jection of cells with antibodies against p110a completely
blocked the insulin-stimulated appearance of actin-rich
projections (Fig. 3, K and L). These data implicate p110a,
rather than hVPS34, as critical for insulin-stimulated rear-
rangement of the actin cytoskeleton.
Figure 2. Characterization of anti-hVPS34 anti-
bodies. (A) Lysates from Sf-9 cells expressing
hVPS34 were immunoprecipitated with anti-
hVPS34 antibody or control IgG. Immune com-
plexes were immobilized on protein A beads,
washed, and then assayed for PI 39-kinase activ-
ity. (B) CHO cells were lysed and proteins were
immunoprecipitated with anti-hVPS34 antibod-
ies. The immune complexes were immobilized
on protein AÐSepharose, washed, and then as-
sayed for PI 39-kinase activity in the presence of
10 mM MgCl2 or 10 mM MnCl2. (C) Recombi-
nant hVPS34 was immunoprecipitated with
anti-hVPS34 antibody and immune complexes
were absorbed to protein AÐSepharose. The
washed beads were incubated in the absence or
presence of hVPS34 peptide at 308C for 30 min
and then assayed for PI 39-kinase activity. (D)
Recombinant hVPS34 (left) or p110a ( right)
was incubated with rabbit IgG, anti-hVPS34 an-
tibody, or anti-p110a antibody (20 mg/ml final)
at 48C for 2 h, and then assayed for PI 39-kinase
activity. (E) Recombinant hVPS34 was incu-
bated with various concentrations of anti-hVPS34
antibody for 2 h at 48C and then assayed for PI
39-kinase activity.Siddhanta et al. Distinct Functions of p110a and hVPS34 PI Kinases 1651
Figure 3. Insulin regulation of the actin cytoskel-
eton requires p110a but not hVPS34. Quiescent
GRC-LR173 cells were injected with 3 mg/ml
rabbit IgG (AÐD), anti-hVPS34 (EÐH) or anti-
p110a (IÐL). The cells were fixed in the absence
(A, B, E, F, I, and J) or presence (C, D, G, H, K,
and L) of 100 nM insulin for 7 min. The cells
were fixed and stained with FITC anti-rabbit IgG
(left) or rhodamine-phalloidin (right). Asterisk,
injected cells on the right. Images were collected
using a Nikon Diaphot inverted microscope with
Nikon 1003 NA 1.25 Achromat optics. The data
is representative of two experiments.
Role of p110a and hVPS34 in Early Endosomal Events
Recent data from Corvera, Stenmark, and their colleagues
have shown that the early endosomal protein EEA1 is dis-
placed from endosomes by wortmannin and binds specifi-
cally to vesicles containing PI[3]P (Patki et al., 1997, 1998;
Gaullier et al., 1998). Although the production of PI(3)P
in the endosomal membrane could be the result of any
of the known PI 39-kinases, the exclusive production of
PI(3)P by hVPS34 would make it a likely candidate. We
therefore tested the effects of the inhibitory antibodies on
the localization of EEA1. In control Trvb-1 cells or cells
injected with rabbit IgG (Fig. 4 A), EEA1 is located in
large vesicular structures scattered throughout the cyto-
plasm. Injection of Trvb-1 cells with anti-p110a antibodies
(Fig. 4 B) had little effect on EEA1. In contrast, in cells in-
jected with anti-hVPS34 antibodies, EEA1 was no longer
associated with small vesicles but concentrated in large
perinuclear structures (Fig. 4 C). This change in the sub-
cellular localization of EEA1 was similar to that seen in
Trvb-1 cells treated with 100 nM wortmannin (Fig. 4, D
and E). These data suggest that hVPS34 is required for the
localization of EEA1, presumably by producing PI(3)P in
the early endosomal membrane.
We also examined the postendocytic sorting of internal-
ized PDGF receptors to a perinuclear compartment, which
is blocked by wortmannin (Joly et al., 1995). HepG2 cells
expressing the wild-type PDGF receptor were incubated
at 48C with mouse anti-PDGF receptor antibodies and 20
ng/ml PDGF, then rapidly warmed to 378C for 10 min to
initiate endocytosis. After fixation, injected cells were vi-
sualized with FITC-labeled anti-rabbit antibodies (Fig. 5,
left) and PDGF receptors were visualized with Cy3-labeledThe Journal of Cell Biology, Volume 143, 1998 1652
anti-mouse antibodies (Fig. 5, right; asterisks, injected
cells). In cells that were fixed before the 10 min incubation
378C, anti-PDGF receptor staining was entirely in the
plasma membrane and was unaffected by injection with
control or antiÐPI 39-kinase antibodies (data not shown).
In cells that were warmed to 378C for 10 min, internalized
receptors accumulated in small peripheral vesicles as well
as a prominent ring of larger perinuclear vesicles (Fig. 5
B). This perinuclear accumulation of PDGF receptors
was not affected by injection with control IgG (Fig. 5, A
and B) or anti-p110a antibodies (Fig. 5, C and D). In both
cases, the distribution of PDGF receptors in injected cells
is the same as that seen in noninjected cells in the same
field. In contrast, injection of cells with inhibitory anti-
hVPS34 antibodies almost completely blocked the peri-
nuclear accumulation of internalized PDGF receptors
(Fig. 5, E and F). The staining in these cells was similar to
that seen in cells treated with 100 nM wortmannin (data
not shown).
The effects of inhibitory anti-hVPS34 antibodies on the
sorting of PDGF receptors was more clearly seen in cells
fixed after 5 min at 378C (Fig. 6). In control cells or cells
injected with rabbit IgG (Fig. 6 A), PDGF receptors could
be seen in small vesicles scattered throughout the cyto-
plasm, as well as large vesicles near the nucleus. Injection
of anti-hVPS34 antibodies (Fig. 6 B) does not block inter-
nalization of PDGF receptors, but the internalized recep-
tors are located in smaller vesicles that are primarily lo-
cated at the cell periphery. These data would be consistent
with a role for hVPS34 in the fusion and/or maturation of
early endosomal vesicles.
Role of p110a and hVPS34 in Transferrin Recycling
We next examined the recycling of endocytosed transfer-
rin, which is significantly slowed in cells treated with 100 nM
wortmannin (Martys et al., 1996; Spiro et al., 1996). Trvb-1
cells were injected with control IgG or anti-PI kinase anti-
bodies, labeled for 2 h with Cy3-transferrin, and washed
into transferrin-free medium. We visualized the injected
cells with FITC-labeled anti-rabbit IgG (Fig. 7, left) and
compared their content of Cy3 transferrin (Fig. 7, right).
None of the antibodies affected the steady state labeling of
CHO cells, observed after the 2-h incubation with Cy3-
transferrin (Fig. 7, A, C, and E); the internalized transfer-
rin accumulated in a diffuse perinuclear compartment as
previously described (McGraw et al., 1987; Martys et al.,
1996). After 60 min in transferrin-free medium, most of
the internalized Cy3-transferrin had effluxed from cells in-
jected with control IgG (Fig. 7 B). Cells injected with anti-
hVPS34 antibodies showed a slightly higher level of resid-
ual Cy3-transferrin after 60 min (Fig. 7 D). In contrast,
cells injected with anti-p110a antibodies showed a persis-
tent labeling with Cy3 after the 60-min incubation in trans-
ferrin-free medium (Fig. 7 F), reflecting a delay in the ef-
flux of internalized Cy3-transferrin. These data are similar
to those obtained from cells treated with 100 nM wort-
mannin (Martys et al., 1996), and suggest that p110a is the
primary wortmannin-sensitive PI 39-kinase involved in
regulation of transferrin recycling.
A 60-min chase in transferrin-free medium was chosen
to maximize the differences between cells injected with
Figure 4. Disruption of EEA1 localization by anti-hVPS34 anti-
bodies. Cells were injected with control IgG (A), anti-p110a (B),
or anti-hVPS34 (C) antibodies. After 2 h the cells were fixed and
stained with FITC anti-rabbit antibodies to identify injected cells
(left) or anti-EEA1 antibodies (right). The Renaissance signal
amplification kit (New England Nuclear) was used to enhance
detection of EEA1. Images were collected using a Bio-Rad MRC
laser scanning confocal microscope (Hercules, CA) with Nikon
603 NA 1.4 Planapo optics (Tokyo, Japan). The data are repre-
sentative of three experiments. Alternatively, cells were incu-
bated in the absence (D) or presence (E) of 100 nM wortmannin
for 30 min, fixed, and then stained for EEA1 as above.Siddhanta et al. Distinct Functions of p110a and hVPS34 PI Kinases 1653
Figure 5. PDGF receptor trafficking requires
hVPS34, but not p110a. HepG2 cells expressing
the human PDGF-b receptor were injected with 3
mg/ml rabbit IgG (A and B), anti-p110a (C and
D) or anti-hVPS34 (E and F). The cells incubated
at 48C with anti-PDGF receptor antibodies and 20
ng/ml PDGF, warmed rapidly to 378C for 10 min,
and then fixed. The cells were stained with FITC
anti-rabbit IgG to labeled injected cells (left) or
Cy3Ðanti-mouse IgG to label PDGF receptors
(right). Asterisk, injected cells on the right. The
data is representative of six experiments. Images
were collected using a Nikon Diaphot inverted
microscope with Nikon 1003 NA 1.25 Achromat
optics.
antiÐPI 39-kinase antibodies versus control IgG. Under
these conditions, hVPS34 antibodies had only a slight ef-
fect. However, when we examined the cells after a 30-min
chase in transferrin-free medium, it was clear that hVPS34
antibodies did reduce the rate of transferrin recycling (Fig.
7 G). To summarize, these data show that both anti-p110a
and anti-hVPS34 antibodies inhibit recycling. Inhibition of
p110a had a greater effect on recycling than inhibition of
hVPS34.
Role of p110a and hVPS34 in Insulin-stimulated 
Mitogenic Signaling
Roche et al. (1994) and ourselves have previously shown
that inhibitory antibodies to p110a block mitogen-stimu-
lated DNA synthesis. To compare the role of p110a and
hVPS34 in mitogenic signaling, GRC-LR173 cells were
injected with control IgG or antiÐPI 39-kinase antibodies,
stimulated with insulin for 16 h and labeled with BrdU.
Surprisingly, injection of anti-hVPS34 as well as anti-
p110a antibodies inhibited insulin-stimulated DNA syn-
thesis by 70% (Fig. 8).
To confirm the unexpected requirement for hVPS34 in
mitogenic signaling, we designed three antisense phosphor-
othioate oligonucleotides derived from NH2-terminal or
internal nucleotide sequences from hVPS34 (Materials
and Methods). We initially tested these oligonucleotides in
HeLa cells, as they were derived from a human sequence
and were more likely to work in a human line. HeLa cells
were difficult to render quiescent; after 2 d without serum
the cells were still 28% BrdU positive, and insulin stimula-
tion caused only a twofold increase in BrdU labeling to
58%. Nonetheless, this increase was completely blocked
by injection of anti-hVPS34 antibody, and was reduced by
60Ð100% by injection of antisense oligonucleotides (data
not shown).
We repeated the experiments in GRC-LR173 cells,
which are more easily acquiesced (Pollard and Stanners,
1979). Insulin stimulated DNA synthesis by more than
10-fold. Injection of AS1 and AS2 inhibited this insulin-
stimulated DNA synthesis by 80 and 90%, respectively,
as compared with a 70% inhibition achieved with anti-
hVPS34 antibodies (Fig. 9 A). AS3 was less effective, in-
hibiting DNA synthesis by z50% (Fig. 9 A). To test theThe Journal of Cell Biology, Volume 143, 1998 1654
specificity of these effects, we synthesized scrambled ver-
sions of the more effective AS1 and AS2 oligonucleotides.
These were only slightly inhibitory in comparison to the
effects seen with the unscrambled oligonucleotides; AS1
and AS2 inhibited DNA synthesis by 87 and 91%, as op-
posed to 35 and 13% inhibition for their scrambled coun-
terparts (Fig. 9 B). These antisense experiments provide a
confirmation of the antibody injection data, using entirely
distinct reagents.
To better define the requirement for hVPS34 in the in-
sulin-stimulated G1ÐS transition, we injected cells with
anti-p110a or anti-hVPS34 antibodies before stimulating
the cells or at various times after insulin stimulation. Con-
sistent with Roche et al. (1994), we find that p110a is re-
quired throughout the first 6 h of insulin stimulation (Fig.
10). By 9 h of insulin stimulation, the cells become largely
independent of p110a. Interestingly, the temporal require-
ment for hVPS34 was different than that for p110a. Al-
though injection of anti-hVPS34 antibodies into cells after
3 h of insulin stimulation inhibited DNA synthesis by over
85%, injection at 6 h inhibited by only 50%, and injection
at 9 h inhibited by only 20%. These data suggest that both
hVPS34 and p110a are required for the insulin-stimulated
G1ÐS transition. However, the requirement for hVPS34 is
limited to an earlier period within G1 than the require-
ment for p110a.
Discussion
These data provide new insights into the role of different
classes of PI 39-kinase in distinct cellular events. We have
examined a number of cellular responses that have been
previously shown to be inhibited by low doses of the PI 39-
kinase inhibitor wortmannin. Our studies have focused on
the wortmannin-sensitive class I (p110a) and class III
(hVPS34) PI 39-kinases. The class II PI 39-kinase are sig-
nificantly less sensitive to wortmannin and are unlikely to
be involved in responses that are inhibited by 50Ð100 nM
wortmannin (Vanhaesebroeck et al., 1997).
p110a can catalyze the production of PI[3]P, PI[3,4]P2,
and PI[3,4,5]P3, whereas hVPS34 is limited to the pro-
duction of PI[3]P (Vanhaesebroeck et al., 1997). Previous
studies have shown that cellular levels of PI[3,4]P2 and
PI[3,4,5]P3 increase in mitogen-stimulated cells, whereas
levels of PI[3]P remain unchanged (Auger et al., 1989;
Kapeller et al., 1991). Furthermore, the yeast VPS34 plays
a role in the regulation of biosynthetic vacuolar sorting
(Schu et al., 1993). Thus, our expectations before begin-
ning these studies was that p110a would be involved in mi-
togen-stimulated responses such as rearrangement of the
cytoskeleton and DNA synthesis, whereas hVPS34 would
be involved in activities such as endocytic sorting. In fact,
the situation is more complex. Both hVPS34 and p110a
Figure 6. Effects of inhibi-
tory anti-hVPS34 antibodies
on PDGF receptor trafficking.
HepG2 cells expressing the
human PDGF-b receptor were
incubated with anti-receptor
antibodies and PDGF at 48C
as above, then warmed to
378C for 5 min. The cells were
fixed and stained as in Fig. 5.
The data is representative of
three separate experiments.
Images were collected using a
Nikon Eclipse E-400 micro-
scope with Nikon 603 NA
1.4 Planapo optics.Siddhanta et al. Distinct Functions of p110a and hVPS34 PI Kinases 1655
are involved in vesicular trafficking and mitogenic signal-
ing, albeit at different steps. In contrast, insulin-stimulated
actin rearrangement requires p110a, but does not require
hVPS34.
PI 39-Kinases and the Organization of the
Actin Cytoskeleton
Previous studies have shown that microinjection of Dp85
(a mutant p85 that lacks p110 binding sites) inhibits insu-
lin-stimulated membrane ruffling in KB cells (Kotani et al.,
1994). Furthermore, Martin et al. (1996b) have shown that
microinjection of an activated p110a construct is sufficient
to induce ruffling and stress fiber breakdown in 3T3-L1
adipocytes or rat-1 fibroblasts, whereas SH2 domains from
p85 were inhibitory. Our finding that p110a is required for
insulin-stimulated actin rearrangement is not surprising,
but serves as a useful control for the specificity of the anti-
bodies with regard to inhibition of p110a- and hVPS34-
dependent responses in intact cells.
PI 39-Kinases in Early Endosomal Function
Inhibition of hVPS34, but not p110a, has pronounced ef-
fects on two early endosomal events: the targeting of
EEA1 to the early endosome, and the postendocytic sort-
ing of the PDGF receptor. These data suggest that the
early endosome is a major site of hVPS34 action. Our find-
ing that hVPS34 is responsible for the targeting of EEA1
is consistent with several recent studies showing that the
FYVE finger of EEA1 binds specifically to the product of
hVPS34, PI(3)P (Gaullier et al., 1998; Patki et al., 1998).
Moreover, expression of EEA1 in S. cerevisiae leads to
a VPS34-dependent accumulation in intracellular mem-
branes (Burd and Emr, 1998). EEA1 in turn is required
for homotypic fusion of early endosomes, and may func-
tion by recruitment of rab5 to the endosomal membrane
(Mills et al., 1998; Simonsen et al., 1998). Thus, the
hVPS34-dependent recruitment of EEA1 plays a critical
role in early endosomal function. It remains to be seen
how hVPS34 itself is targeted to the endosomal mem-
Figure 7. Role of PI 39-kinases in transferrin receptor recycling. CHO cells expressing the human transferrin receptor (Trvb-1) were in-
jected with 3 mg/ml rabbit IgG (A and B), anti-hVPS34 (C, D, and G) or anti-p110a (E and F). The cells were labeled with Cy3-transfer-
rin for 2 h, and then fixed immediately (A, C, and E) or fixed after a 30- (G) or 60-min (B, D, and F) incubation in transferrin-free me-
dium. The cells were stained with FITC-labeled anti-rabbit IgG to label injected cells (left). Right, Cy3-transferrin. The data is
representative of three experiments. Images were collected using a Nikon Eclipse E-400 microscope with Nikon 603 NA 1.4 Planapo
optics.The Journal of Cell Biology, Volume 143, 1998 1656
brane, perhaps via binding to the myristylated p150 (Pana-
retou et al., 1997). We also cannot yet explain the perinuclear
localization of EEA1 in cells injected with anti-hVPS34
antibodies or treated with wortmannin. It is possible that
this reflects the continued activity of a class II PI 39-kinase,
which would not be inhibited by either our antibodies or
100 nM wortmannin.
Inhibitory antibodies to hVPS34 also disrupt the posten-
docytic trafficking of the PDGF receptor, consistent with
the ability of low-dose wortmannin to block PDGF recep-
tor targeting and degradation (Joly et al., 1995). Although
this could be due to an early endosomal defect, we cannot
rule out additional sites of action at the late endosome or
lysosome. The the involvement of hVPS34 in PDGF re-
ceptor trafficking may be analogous to the role of yeast
VPS34 in vacuolar targeting (Herman et al., 1992), and is
consistent with data from numerous laboratories showing
that wortmannin inhibits both early and late endosomal
fusion events and lysosomal delivery (for review see De
Camilli et al., 1996).
Although our data suggest that p110a is not involved in
early endosomal function, it should be noted that CHO
cells contain both p110a and p110b. p110b also couples to
p85 and should be similarly regulated by insulin or PDGF
(Hu et al., 1993). Thus, it is possible that p85/p110b
complexes play a role in the regulation of PDGF receptor
sorting or EEA1 localization that augments the role of
hVPS34. Such a requirement would be consistent with the
finding that mutation of the p85 binding sites in the PDGF
receptor mimic the effects of wortmannin on receptor
sorting (Joly et al., 1994). The testing of anti-p110b anti-
bodies is ongoing in the laboratory and will help to resolve
this question.
PI 39-Kinases in Transferrin Recycling
The recycling of transferrin receptors in Trvb-1 cells was
significantly slowed by treatment of cells with wortmannin
(Martys et al., 1996). The effects of this drug on the distri-
bution of transferrin receptors was half-maximal at 30 nM
wortmannin, consistent with the involvement of a mam-
malian class I or III PI 39-kinase (Vanhaesebroeck et al.,
1997). We now find that inhibition of both p110a and to a
Figure 8. Inhibition of insu-
lin-stimulated DNA synthesis
by anti-PI kinase antibodies.
GRC-LR173 cells were qui-
esced in serum containing
1% FBS for 48 h, then in-
jected with 3 mg/ml rabbit
IgG, anti-p110a, or anti-
hVPS34. The cells were then
incubated in the absence or
presence of insulin for 16 h
plus an additional 2 h in 100
mM BrdU, fixed, and then
stained with FITC anti-rab-
bit IgG to labeled injected
cells, or mouse anti-BrdU an-
tibodies and Cy3Ðanti-mouse
antibodies to label cells in S phase. The percentage of injected
cells that were labeled with BrdU was calculated; greater than
100 cells were counted per condition. The data are the mean 6
SEM from five experiments.
Figure 9. Inhibition of insulin-stimulated DNA synthesis by anti-
sense oligonucleotides to hVPS34. (A) GRC-LR173 cells were
incubated in medium containing 1% FBS for 36 h, injected with 3
mg/ml rabbit IgG, anti-hVPS34 antibody, or rabbit IgG plus 10 mM
antisense oligonucleotide (AS-1, AS-2, or AS-3). 8 h later, the
cells were stimulated without or with 100 nM insulin for 16 h fol-
lowed by 2 h in 100 mM BrdU. The cells were fixed and BrdU in-
corporation in injected cells was analyzed as in Fig. 8. The data
are the mean 6 SEM from four experiments. (B) Cells were
treated as above, but were injected with antisense oligonucle-
otides (AS-1 and AS-2) or their scrambled counterparts (SCR-1
and SCR-2). Insulin-stimulated BrdU incorporation was mea-
sured as above. The data are the mean 6 SEM from two (AS-2
and SRC-2) or four (AS-1 and SCR-1) experiments.
Figure 10. Time-dependent inhibition of insulin-stimulated DNA
synthesis by antiÐPI 39-kinase antibodies. Quiescent GRC-
LR173 cells were injected with 3 mg/ml rabbit IgG, anti-p110a,
or anti-hVPS34 antibodies, and then stimulated with insulin. Al-
ternatively, the cells were injected at various times after insulin
stimulation. After 16 h of insulin stimulation and an additional 2-h
incubation in 100 mM BrdU, the cells were fixed. BrdU incorpo-
ration was calculated as in Fig. 8. The data are the mean 6 SEM
from three experiments.Siddhanta et al. Distinct Functions of p110a and hVPS34 PI Kinases 1657
lesser extent hVPS34 replicates the wortmannin pheno-
type with regard to transferrin recycling.
The role of the p85/p110a PI 39-kinase as a positive reg-
ulatory of receptor recycling is consistent the fact that in-
sulin, which activates p85/p110 (Ruderman et al., 1990),
enhances the recycling of a number of constitutively recy-
cling receptors (Wardzala et al., 1984; Davis et al., 1986).
Moreover, the p85/p110 PI 39-kinase is required for the in-
sulin stimulation of Glut-4 recycling to the plasma mem-
brane (Okada et al., 1994; Cheatham et al., 1994) and
overexpression of p110a increases Glut 4 recycling in sev-
eral systems (Martin et al., 1996a; Frevert and Kahn,
1997). Inhibition of hVPS34 also delays transferrin recy-
cling, but to a much smaller extent. The different degrees
of inhibition observed with anti-hVPS34 versus anti p110a
antibodies could reflect differential recruitment of a regu-
latory protein that binds to PI[3,4,5]P3 with higher affinity
than to PI[3]P. Alternatively, hVPS34 and p110a could act
on distinct proteins within the recycling compartment.
PI 39-Kinases in Mitogenic Signaling
The most striking result in this study is the requirement for
the hVPS34 in insulin-stimulated DNA synthesis. This re-
sult has been verified using two entirely different ap-
proaches to reduce hVPS34 activity and/or expression.
Our data suggest that hVPS34 is specifically required for
entry of insulin-stimulated cells into S phase.
Previous studies have shown that the levels of PI[3,4]P2
and PI[3,4,5]P3 increase acutely in response to mitogens
such as insulin or PDGF, whereas the levels of PI[3]P does
not change (Auger et al., 1989; Kapeller et al., 1991).
hVPS34 is restricted to the production of PI[3]P, and it is
therefore surprising that its activity is required for mito-
genic signaling. It may be that constitutive levels of PI[3]P
are required for cellular systems that are needed during
the transition to S phase. Alternatively, PI[3]P levels may
be acutely regulated in specific intracellular locations that
are not detectable when whole cell lipid production is
measured. Although we do not yet know the function of
PI[3]P in mitogenic signaling, our data suggests that the
products of hVPS34 are required only during the first 6 h
of insulin stimulation. In contrast, the products of p110a
are still critical at 6Ð9 h of insulin stimulation.
One can propose three general mechanisms by which
hVPS34 could act during mitogenic signaling. First, as sug-
gested above, the constitutive production of PI[3]P could
be required for a cellular process that is needed during
early G1. For example, it is possible that normal traffick-
ing of tyrosine kinase receptors is required for efficient
signal transduction. However, insulin receptor signaling is
relatively normal in cells expressing a dominant-negative
mutant of dynamin, which blocks coated pit-mediated en-
docytosis (Ceresa et al., 1998). Second, insulin could regu-
late the activity and/or subcellular distribution of hVPS34,
leading to the production of PI[3]P at specific intracellular
locales. This PI[3]P could in turn recruit specific PI[3]P-
binding proteins involved in mitogenic signaling. Finally, a
third hypothesis takes note of the potential conversion of
PI[3]P to higher-order polyphosphoinositides. A recent
finding by Anderson and colleagues (Zhang et al., 1997)
shows that PI[4]-5 kinases can convert PI[3]P to PI[3,4,5]P3.
If this pathway is a significant source of PI[3,4]P2 and
PI[3,4,5]P3 in mitogen-stimulated cells, then reductions in
the PI[3]P pool could affect intracellular levels of PI[3,4]P2
and PI[3,4,5]P3. In this way, changes in PI[3]P levels could
influence the production of the 3-phosphoinositides that
have known signaling functions (Toker and Cantley,
1997). Alternatively, two groups have identified a novel
lipid, PI[3,5]P2, in yeast and mammalian cells (Dove et al.,
1997; Tolias et al., 1998). In S. cerevisiae, PI[3,5]P2 is pro-
duced in response to osmotic stress by a pathway that re-
quires VPS34 but is independent of the Hog1 mitogen-
activated protein kinases (Dove et al., 1997). These data
suggest a role for VPS34 in signal transduction, which
would be consistent with our findings regarding hVPS34
and mitogenesis.
In summary, we have examined the roles of type I and
type III PI 39-kinases in mammalian cells. p110a and
hVPS34 PI 39-kinases both effect the endoctyic system:
hVPS34 regulates events in the early endosome and to a
lesser extent the recycling compartment, whereas p110a
primarily regulates the recycling pathway. Furthermore,
both p110a and hVPS34 are necessary for insulin-stim-
ulated DNA synthesis. However, the requirement for
hVPS34 occurs during a narrower time window in G1 than
the requirement for p110a, suggesting that these enzymes
perform different functions in mitogenic signaling. The de-
termination of the distinct roles played by different PI 39-
kinase isoforms adds a new layer of complexity to the
functions of these lipid kinases in cellular signaling.
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